Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 6/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 6/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111692 | 0.81 | PDE3B (0.34) | HTR1AHTR1DHTR2CHTR7HTR5A | |
| SCHEMBL5119433 | 0.77 | HTR5A (0.47) | HTR1AHTR1DHTR2CHTR7HTR5A | |
| SCHEMBL5124908 | 0.73 | NR3C1 (0.30) | — | |
| SCHEMBL5119353 | 0.71 | CA2 (0.35) | — | |
| SCHEMBL5112467 | 0.71 | NOTUM (0.37) | BRD4 | |
| SCHEMBL5111338 | 0.71 | PGR (0.45) | BRD4CREBBP | |
| SCHEMBL11208873 | 0.66 | HTR5A (0.41) | HTR5ABRD4CREBBP | |
| SCHEMBL31180367 | 0.65 | HTR2A (0.37) | HTR2C | |
| SCHEMBL5115070 | 0.65 | PGR (0.47) | — | |
| SCHEMBL10952355 | 0.65 | BRD4 (0.40) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442696-B2 | Mineralocorticoid receptor modulator compounds, processes for their preparation, and their uses | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | LIGAND PHARMACEUTICALS INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2006010142-A2 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | LIGAND PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197520-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USES | NR3C2, MC2R, NR3C1 | ABCC9 4682/4885KCNJ11 2171/4885HTR1A 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.